|
 |
DovonexThis page contains recent news articles, when available, and an overview of Dovonex but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The company launched calcipotriene solution in the 0.005% strength, a synthetic vitamin D3 derivative and generic version of Leo Pharma's Dovonex Scalp ... Drug Store News (blog) Warner Chilcott: An Undervalued Growth Play - Dec 21, 2009 ...licensing rights in the US to distribute its Taclonex and Dovonex products, and acquire certain asset related to the distribution of those products. ... Sumfolio.com Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2009 - Nov 9, 2009 Net sales of DOVONEX decreased by $2.6 million, or 9.9%, in the quarter ended September 30, 2009, compared with the prior year quarter. ... CNNMoney.com (press release) Warner Chilcott (NASDAQ: WCRZ) 3Q Profit Rise on Leo Pharma - Nov 9, 2009 ...returned the license rights to a group of products including the psoriasis treatments Taclonex and Taclonex Scalp, and Dovonex ointment, to Leo Pharma. ... TransWorldNews (press release) Warner Chilcott第三å£ç›ˆåˆ©åŠ²å?‡ - Nov 9, 2009 ...这些产å“?包括牛皮癣治疗è?¯ç‰©Taclonex与Taclonex Scalp，以å?ŠDovonexè?¯è†?ã€‚æ ¹æ?®æ–°å??议，Warner Chilcott将代销这些产å“?至2009年底。 扣除æ?¥è‡ªLeo交易的收益å?Žï¼Œè¯¥å…¬å?¸å½“ ... 新浪网 Bristol's Earnings Rise - Apr 28, 2006 Net profit, which included a one-time gain of $200 million for the sale of United States marketing rights for the psoriasis drug Dovonex, rose to $714 ... New York Times Hi-Tech: Tentative OK on Generic Dovonex - Mar 23, 2007 US firm Hi-Tech Pharmacal said Friday it has tentative approval to market a generic version of Warner Chilcott's topical drug Dovonex. ... RedOrbit Warner Chilcott issues 2008 outlook - Jan 28, 2008 The guidance assumes generic competition for psoriasis treatment Dovonex solution in the first quarter of 2008, and for premenstrual dysphoric disorder ... Boston Globe Incyte rises after reporting psoriasis drug data - Sep 18, 2008 ...in lesion severity compared with those who were treated with Warner Chilcott Ltd.'s drug Dovonex or Schering-Plough's topical steroid Diprolene. ... Boston Globe WARNER CHILCOTT LIMITED at Morgan Stanley Pharmaceutical CEOs … - Jan 4, 2007 So moving forward we actually see this as a franchise; perhaps when we initially looked at it we said we've got to grow Taclonex at the expense of Dovonex. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com New psoriasis treatments offer hope - Nov 9, 2005 Dovonex, which is related to vitamin D, is another skin-applied medicine, as is Tazorac, which belongs to the vitamin A family. ... $3.50 - The Gazette - NewsBank Warner Chilcott Reports Operating Results for the Quarter ended March... - May 15, 2006 In January we closed the acquisition of DOVONEX(R) and the FDA approved TACLONEX(R). ... Excluding DOVONEX(R) net sales from the current year quarter and ... Free with registration - PR Newswire - AccessMyLibrary.com Menu of effective psoriasis medicines is long - Feb 22, 2008 My doctor prescribed Dovonex cream, but it isn't working all that well for me. ... Your Dovonex (a vitamin D relative) quite often successfully puts a lid ... Chattanooga Times Free Press Dovonex.(Drug overview) - Jan 22, 2007 Dovonex is prescribed to help clear up the scaly skin condition known as psoriasis. A synthetic form of vitamin D, it is available in cream and ointment ... Free with registration - PDR Family Guide to Prescription Drugs - AccessMyLibrary.com Turmeric helps clear up psoriasis - Jan 17, 2008 The dermatologist he saw prescribed Dovonex, Capex and clobetasol. ... He had discontinued using Dovonex and wants to drop the Capex and clobetasol next. ... Youngstown Vindicator Warner Chilcott Limited Announces Operating Results for the 1st... - May 11, 2007 Sales of DOVONEX increased $8.1 million, or 23.8%, compared with the prior year ... Adjusted for the DOVONEX inventory step-up in the prior year quarter, ... $4.95 - M2 Presswire - ECNext Warner Chilcott Reports Operating Results for the Quarter ended March... - Mar 31, 2006 In January we closed the acquisition of DOVONEX(R) and the FDA approved TACLONEX(R). ... Excluding DOVONEX(R) net sales from the current year quarter and ... prnewswire.com Moody's revises Warner Chilcott outlook. - Oct 9, 2006 Moody's said the ratings upgrade also considers the potential growth in cash flow from the company's Dovonex/Taclonex topical psoriasis treatment franchise, ... Free with registration - Europe Intelligence Wire - AccessMyLibrary.com IN BRIEF: Dovonex calcipotriol. - Mar 31, 2007 Dovonex calcipotriol ointment is to be withdrawn on April 16, Leo Pharma has announced. The organisation made the decision based on the commercial viability ... $9.94 - Chemist & Druggist - Alacra Store IN BRIEF: Dovonex calcipotriol.(Brief article) - Mar 31, 2007 Dovonex calcipotriol ointment is to be withdrawn on April 16, Leo Pharma has announced. The organisation made the decision based on the commercial viability ... $4.95 - Chemist & Druggist - ECNext Nonsteroidal Maintenance Therapies for Psoriasis Evaluated - Sep 18, 2006 Betamethasone was significantly more effective than Elidel or Dovonex at reducing ... Concentrations of the drugs were 1% for Elidel, 0.005% for Dovonex, ... MedPage Today Warner Chilcott Reports Operating Results for the Quarter and Six... - Jun 30, 2006 The January 1, 2006 acquisition of DOVONEX(R) was a significant factor driving the ... Sales of DOVONEX(R) accounted for $34.3 million of the increase in ... prnewswire.com Warner Chilcott Reports Operating Results for the Quarter Ended June... - Aug 10, 2007 Sales of DOVONEX decreased $6.4 million or 16.1% in the quarter ended June 30, ... The decline in filled prescriptions and contraction of DOVONEX pipeline ... Free with registration - PR Newswire - AccessMyLibrary.com Warner Chilcott Reports Operating Results for the Quarter and Six... - Aug 11, 2006 The January 1, 2006 acquisition of DOVONEX(R) was a significant factor driving the ... Sales of DOVONEX(R) accounted for $34.3 million of the increase in ... $4.95 - PR Newswire - ECNext Warner Chilcott Reports Operating Results for the Quarter Ended June... - Jun 30, 2007 Sales of DOVONEX decreased $6.4 million or 16.1% in the quarter ended June 30, ... The decline in filled prescriptions and contraction of DOVONEX pipeline ... prnewswire.com Warner Chilcott Reports Operating Results for the Quarter and Year … - Dec 31, 2006 During the quarter ended December 31, 2005 we promoted DOVONEX for Bristol-Myers Squibb and ... Sales of DOVONEX, which we acquired on January 1, 2006, ... prnewswire.com Press Release: Warner Chilcott Reports Operating Results for the... - May 15, 2006 In January we closed the acquisition of DOVONEX(R) and the FDA approved TACLONEX(R). ... Excluding DOVONEX(R) net sales from the current year quarter and ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: FDA Approves Taclonex Scalp(R) - Once Daily Therapy … - May 12, 2008 States to TACLONEX, TACLONEX SCALP, DOVONEX and all ... States to TACLONEX, TACLONEX SCALP, DOVONEX and all ... M2 Presswire. Article: News and FDA Updates ... Pay-Per-View - PR Newswire - HighBeam Research Warner Chilcott Reports Operating Results for the Quarter and Year … - Mar 7, 2007 During the quarter ended December 31, 2005 we promoted DOVONEX for Bristol-Myers Squibb and ... Sales of DOVONEX, which we acquired on January 1, 2006, ... $4.95 - PR Newswire - ECNext Warner Chilcott Reports Operating Results for the Quarter ended … - Nov 14, 2006 The increase was driven by sales of LOESTRIN(R) 24 FE, DOVONEX(R) and ... In 2005, the Company promoted DOVONEX(R) for Bristol-Myers and earned $5.0 million ... $4.95 - PR Newswire - ECNext Calcipotrio (Dovobet[R]) ointment in combination with UVB therapy for... - Jun 1, 2006 His previous treatments include Dovonex, Protopic[R], and various topical steroids. ... Previous treatments include tar preparations, anthralin, Dovonex, ... Free with registration - Dermatology Nursing - AccessMyLibrary.com Article: Requiem for a much-needed drug.(Letters)(Letter to the... - Feb 1, 2008 Revenue under Warner Chilcott's contract to co-promote Dovonex (calcipotriene ... Warner Chilcott is presently marketing ... psoriasis drug Dovonex ... Pay-Per-View - Skin & Allergy News - HighBeam Research Living with psoriasis.(Patients' Perspectives) - Apr 1, 2005 When Dovonex[R] was approved that worked well, but intermittently. I used tanning beds, which seemed to be the most effective with the Dovonex. ... $4.95 - Dermatology Nursing - ECNext Warner Chilcott Reports Operating Results for the Quarter Ended … - Nov 9, 2007 Sales of DOVONEX decreased $3.9 million, or 10.8%, in the quarter ended ... We believe the decline in filled prescriptions of DOVONEX in the quarter ended ... $4.95 - PR Newswire - ECNext FINAL TRANSCRIPT - May 9, 2008 Revenue from Dovonex, Taclonex franchise totaled 70.1 million in first quarter '08 ... Sales of Dovonex decreased $8.7 million in the first quarter compared ... $54.00 - Thomson StreetEvents - Alacra Store Warner Chilcott's US$1bn IPO: a value proposition - Sep 23, 2006 The acquisition of Dovonex, a psoriasis drug, from Bristol Meyers at the beginning of this year helped expand its product offering. The launch of Taclonex, ... International Financing Review - International Financing Review Q4 2005 Warner Chilcott PLC Earnings Conference Call - Part 2. - Mar 31, 2006 RACHEL GOLDER: You mentioned Dovonex, about 130 million in revenues in '05. ... RACHEL GOLDER: No, that's fine, on Dovonex. I have a couple more, ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Manhattan Pharmaceuticals' Topical Psoriasis Treatment in Phase IIa … - Dec 28, 2005 The most widely prescribed non-steroidal compound is a topical form of calcipotriene (brand name Dovonex(R)), which has been owned and promoted by a variety ... Free with registration - PR Newswire - AccessMyLibrary.com Merger and Acquisition Scenario - Jan 26, 2008 During the year ended December 31, 2006, the Company completed the acquisition of the United States sales and marketing rights to DOVONEX and obtained ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jul 26, 2008 Doryx (Doxycycline Hyclate Delayed Release); Estrostep Fe (Norethindrone Acetate/Ethinyl Estradiol); Dovonex (Calcipotriene) ... $250.00 - Revere Reports - Revere Psoriasis sufferers to get relief - without steroids - from Israeli... - Oct 28, 2007 Despite the fact that the active ingredient in DermiPsor's ointment was not optimized, it performed well in comparison to Dovonex. ... Israel 21C Merger and Acquisition Scenario - Nov 22, 2008 Doryx (Doxycycline Hyclate Delayed Release); Estrostep Fe (Norethindrone Acetate/Ethinyl Estradiol); Dovonex (Calcipotriene); Taclonex Scalp Gel ... $250.00 - Revere Reports - Revere Article: Approval gives Fougera a first.(RX RETAIL PHARMACY: Generic ... - Jun 30, 2008 The generic formulation is comparable to Dovonex by Warner-Chilcott. Fougera's calcipotriene topical solution is indicated for the topical treatment of ... Pay-Per-View - Chain Drug Review - HighBeam Research LEO Pharma and Warner Chilcott Announce Agreements for Expansion of … - Sep 15, 2005 Warner Chilcott is presently marketing Dovonex(R) under a co- promotion deal ... LEO Pharma's Dovonex(R), the leading non-steroidal topical treatment for ... $4.95 - PR Newswire - ECNext Merger and Acquisition Scenario - Apr 7, 2007 Dovonex (Calcipotriene). Vitamin D Analogs/Steroidal Anti-Inflammatory Drugs (SAID). Therapeutics that treat psoriasis by providing vitamin D-like compounds ... $250.00 - Revere Reports - Revere Stock Market Update, IPO profiles, Earnings Call Transcripts,... - Jun 9, 2006 On January 1, 2006 the Compny purchased the rights to exclusively market and sell Dovonex in the United States from Bristol-Myers. ... 123Jump.com Merger and Acquisition Scenario - Jun 16, 2007 Dovonex (Calcipotriene). Vitamin D Analogs/Steroidal Anti-Inflammatory Drugs (SAID). Therapeutics that treat psoriasis by providing vitamin D-like compounds ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jun 30, 2007 Dovonex (Calcipotriene). Vitamin D Analogs/Steroidal Anti-Inflammatory Drugs (SAID). Therapeutics that treat psoriasis by providing vitamin D-like compounds ... $250.00 - Revere Reports - Revere Press Release: Taclonex(R) New Dual-Action Topical Therapy for Plaque... - Apr 3, 2006 LEO Pharma ... exclusive licensee of Taclonex(R) and Dovonex(R) in the United States. Warner Chilcott expects to launch Taclonex(R) in the first ... ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Sep 23, 2006 Dovonex (Calcipotriene). Vitamin D Analogs/Steroidal Anti-Inflammatory Drugs (SAID). Therapeutics that treat psoriasis by providing vitamin D-like compounds ... $250.00 - Revere Reports - Revere Chronic plaque psoriasis. - Feb 15, 2006 Vitamin D derivatives Calcipotriene Limit dosage (Dovonex) to 100 g per week to avoid hypercalcemia. Topical retinoids Tazarotene (Tazorac) Obtain negative ... Free with registration - American Family Physician - AccessMyLibrary.com FDA Approves Taclonex Scalp(R) Once Daily Therapy For Treatment Of … - May 14, 2008 Warner Chilcott is LEO Pharma's exclusive licensee of Taclonex(R) and Dovonex(R) products in the United States. Warner Chilcott expects to launch Taclonex ... Medical News Today - Medical News Today (press release) Chronic plaque psoriasis. - Feb 15, 2006 Vitamin D derivatives Calcipotriene Limit dosage (Dovonex) to 100 g per week to avoid hypercalcemia. Topical retinoids Tazarotene (Tazorac) Obtain negative ... $4.95 - American Family Physician - ECNext Article: PsychEd poll. - Psychopharmacology Educational Updates ( … - Nov 1, 2005 Article: WESTWOOD-SQUIBB ANNOUNCES THE INTRODUCTION OF DOVONEX -- A ... PR Newswire; March 10, 1994 ; 700+ words ...NEW YORK, March 10 /PRNewswire/ -- There ... Pay-Per-View - Psychopharmacology Educational Updates - HighBeam Research Turmeric helps ease itchy psoriasis - Jan 12, 2008 The dermatologist he saw prescribed Dovonex, Capex and clobetasol. ... He had discontinued using Dovonex and wants to drop the Capex and clobetasol next. ... $2.95 - Bradenton Herald - NewsBank FDA Approves Psoriasis Treatment - May 20, 2008 The approval is good news for the Leo Pharma-Warner Chilcott partnership, which covers both Taclonex brands and Dovonex. A generic version of Dovonex ... FDA news - FDA news (subscription) Q4 2007 WARNER CHILCOTT LIMITED Earnings Conference Call - Final … - Feb 29, 2008 Revenue from Dovonex/Taclonex franchise totaled $67.8 million in the fourth quarter of '07. We continue our efforts to promote the use of Taclonex as a ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Event Brief of Q1 2006 Bristol-Myers Squibb Earnings Conference Call ... - Apr 27, 2006 Excluding the impact of the divestiture of Dovonex and the consumer medicines business in 3Q05, volumes would have been. up 2%. 4. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com FDA Approves Taclonex(R) - Once Daily Therapy for Treatment of … - Jan 10, 2006 Warner Chilcott acquired the US marketing rights for Dovonex(R) (calcipotriene 0.005%), the leading non-steroidal topical treatment for psoriasis in the US, ... Free with registration - PR Newswire - AccessMyLibrary.com Comments by Martin Pickering - Jul 11, 2008 Dovobet (a mix of Dovonex and Betnovate) helps to soften the skin and to reduce the ... Dovonex by itself is an emollient and Betnovate is a cortisone which ... Workplace Law Network - Workplace Law Network (subscription) Warner Chilcottå°†å?‘è¡Œ13亿美元åˆ?始股 - Sep 6, 2006 ...上年å?ŒæœŸï¼ŒWarner Chilcott完æˆ?了对Dovonex美国市场销售和行销æ?ƒçš„收è´ï¼Œè´ä»·ä¸º2亿520 万美元，å?Œæ—¶ç»ˆæ¢ ... 在截至6月30日的å…个月ä¸ï¼ŒDovonexçš„è?¥æ”¶æ€»è®¡7370万美元。 ... 新浪网 Merger and Acquisition Scenario - Jun 23, 2007 During the year ended December 31, 2006, the Company completed the acquisition of the United States sales and marketing rights to DOVONEX and obtained ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 13, 2008 Doryx (Doxycycline Hyclate Delayed Release); Estrostep Fe (Norethindrone Acetate/Ethinyl Estradiol); Dovonex (Calcipotriene); Taclonex Scalp Gel ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 23, 2006 On January 1, 2006, Warner Chilcott acquired the United States sales and marketing rights to the Dovonex branded prescription pharmaceutical products in the ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jan 27, 2007 On January 1, 2006, Warner Chilcott acquired the United States sales and marketing rights to the Dovonex branded prescription pharmaceutical products in the ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 12, 2007 During the year ended December 31, 2006, the Company completed the acquisition of the United States sales and marketing rights to DOVONEX and obtained ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 1, 2008 Doryx (Doxycycline Hyclate Delayed Release); Estrostep Fe (Norethindrone Acetate/Ethinyl Estradiol); Dovonex (Calcipotriene) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jan 6, 2007 On January 1, 2006, Warner Chilcott acquired the United States sales and marketing rights to the Dovonex branded prescription pharmaceutical products in the ... $250.00 - Revere Reports - Revere Press Release: Warner Chilcott Reports Operating Results for the... - Mar 7, 2007 During the quarter ended December 31, 2005 we promoted DOVONEX for Bristol-Myers Squibb and earned $4.9 million of co-promotion revenue. ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Nov 4, 2006 On January 1, 2006, Warner Chilcott acquired the United States sales and marketing rights to the Dovonex branded prescription pharmaceutical products in the ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 16, 2006 On January 1, 2006, Warner Chilcott acquired the United States sales and marketing rights to the Dovonex branded prescription pharmaceutical products in the ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Oct 25, 2008 Doryx (Doxycycline Hyclate Delayed Release); Estrostep Fe (Norethindrone Acetate/Ethinyl Estradiol); Dovonex (Calcipotriene) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 17, 2008 Doryx (Doxycycline Hyclate Delayed Release); Estrostep Fe (Norethindrone Acetate/Ethinyl Estradiol); Dovonex (Calcipotriene); Taclonex Scalp Gel ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 27, 2008 Doryx (Doxycycline Hyclate Delayed Release); Estrostep Fe (Norethindrone Acetate/Ethinyl Estradiol); Dovonex (Calcipotriene); Taclonex Scalp Gel ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 Doryx (Doxycycline Hyclate Delayed Release); Estrostep Fe (Norethindrone Acetate/Ethinyl Estradiol); Dovonex (Calcipotriene) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jul 12, 2008 Doryx (Doxycycline Hyclate Delayed Release); Estrostep Fe (Norethindrone Acetate/Ethinyl Estradiol); Dovonex (Calcipotriene) ... $250.00 - Revere Reports - Revere Press Release: FDA Approves Taclonex(R) - Once Daily Therapy for … - Jan 10, 2006 Warner Chilcott acquired the U.S. marketing rights for Dovonex(R) (calcipotriene 0.005%), the leading non-steroidal topical treatment for psoriasis in the ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Aug 2, 2008 Doryx (Doxycycline Hyclate Delayed Release); Estrostep Fe (Norethindrone Acetate/Ethinyl Estradiol); Dovonex (Calcipotriene) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 20, 2008 Doryx (Doxycycline Hyclate Delayed Release); Estrostep Fe (Norethindrone Acetate/Ethinyl Estradiol); Dovonex (Calcipotriene); Taclonex Scalp Gel ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 On January 1, 2006, Warner Chilcott acquired the United States sales and marketing rights to the Dovonex branded prescription pharmaceutical products in the ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 23, 2006 On January 1, 2006, Warner Chilcott acquired the United States sales and marketing rights to the Dovonex branded prescription pharmaceutical products in the ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 4, 2006 On January 1, 2006, Warner Chilcott acquired the United States sales and marketing rights to the Dovonex branded prescription pharmaceutical products in the ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 16, 2006 On January 1, 2006, Warner Chilcott acquired the United States sales and marketing rights to the Dovonex branded prescription pharmaceutical products in the ... $250.00 - Revere Reports - Revere Press Release: Fougera First-to-Market With Calcipotriene Topical … - May 6, 2008 The generic formulation compares to Dovonex(R) by Warner-Chilcott. (Photo: http://www.newscom.com/cgi-bin/prnh/20080506/NYTU034 ) ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Jan 26, 2008 During the year ended December 31, 2006, the Company completed the acquisition of the United States sales and marketing rights to DOVONEX and obtained ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 10, 2007 During the year ended December 31, 2006, the Company completed the acquisition of the United States sales and marketing rights to DOVONEX and obtained ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 23, 2006 On January 1, 2006, Warner Chilcott acquired the United States sales and marketing rights to the Dovonex branded prescription pharmaceutical products in the ... $250.00 - Revere Reports - Revere Drug patent expirations (2007-2009). - Apr 2, 2007 20, 2008 Effexor/XR June 13, 2008 Zymar June 25, 2008 Dovonex June 29, 2008 Kytril June 29, 2008 Risperdal June 29, 2008 Depakote July 29, 2008 Advair Aug. ... $4.95 - Drug Topics - ECNext Merger and Acquisition Scenario - May 3, 2008 Doryx (Doxycycline Hyclate Delayed Release); Estrostep Fe (Norethindrone Acetate/Ethinyl Estradiol); Dovonex (Calcipotriene) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 19, 2007 During the year ended December 31, 2006, the Company completed the acquisition of the United States sales and marketing rights to DOVONEX and obtained ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 5, 2008 Doryx (Doxycycline Hyclate Delayed Release); Estrostep Fe (Norethindrone Acetate/Ethinyl Estradiol); Dovonex (Calcipotriene) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 13, 2008 Doryx (Doxycycline Hyclate Delayed Release); Estrostep Fe (Norethindrone Acetate/Ethinyl Estradiol); Dovonex (Calcipotriene); Taclonex Scalp Gel ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Aug 16, 2008 Doryx (Doxycycline Hyclate Delayed Release); Estrostep Fe (Norethindrone Acetate/Ethinyl Estradiol); Dovonex (Calcipotriene); Taclonex Scalp Gel ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 8, 2008 During the year ended December 31, 2006, the Company completed the acquisition of the United States sales and marketing rights to DOVONEX and obtained ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 13, 2008 Doryx (Doxycycline Hyclate Delayed Release); Estrostep Fe (Norethindrone Acetate/Ethinyl Estradiol); Dovonex (Calcipotriene); Taclonex Scalp Gel ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 29, 2008 Doryx (Doxycycline Hyclate Delayed Release); Estrostep Fe (Norethindrone Acetate/Ethinyl Estradiol); Dovonex (Calcipotriene); Taclonex Scalp Gel ... $250.00 - Revere Reports - Revere Article: Generic versions of Actiq, Balziva introduced by Barr.(RX... - Oct 23, 2006 ...agreement with a subsidiary of Warner Chilcott Limited (NASDAQ:WCRX) to market the authorized generic version of Warner Chilcott's Dovonex(R) Scalp . ... Pay-Per-View - Chain Drug Review - HighBeam Research Merger and Acquisition Scenario - Jul 14, 2007 During the year ended December 31, 2006, the Company completed the acquisition of the United States sales and marketing rights to DOVONEX and obtained ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 23, 2006 On January 1, 2006, Warner Chilcott acquired the United States sales and marketing rights to the Dovonex branded prescription pharmaceutical products in the ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 23, 2006 On January 1, 2006, Warner Chilcott acquired the United States sales and marketing rights to the Dovonex branded prescription pharmaceutical products in the ... $250.00 - Revere Reports - Revere Warner Chilcott Reports Results for the Quarter and Nine Months ended... - Sep 30, 2005 Revenue under our contract to co-promote DOVONEX(R) was $5.0 million, a $2.0 million increase over the prior year quarter. Gross Profit on Product Net Sales ... prnewswire.com Warner Chilcott Reports Operating Results for the Year and the... - Dec 31, 2005 Revenue under our contract to co-promote DOVONEX(R) was $20.9 million, a $7.6 million increase over 2004. For the quarter ended December 31, 2005, ... prnewswire.com La FDA autorise Taclonex Scalp(R) - un traitement uniquotidien du … - May 12, 2008 Taclonex Scalp(R) représente un ajout passionnant à notre franchise Taclonex(R) et Dovonex(R) et élargit les options de traitement des patients souffrant ... Euroinvestor La FDA aprueba Taclonex Scalp(R), un tratamiento para la psoriasis... - May 13, 2008 Warner Chilcott es el licenciatario exclusivo de LEO Pharma de los productos Taclonex(R) y Dovonex(R) en Estados Unidos. Warner Chilcott espera lanzar ... acceso.com Warner Chilcott Reports Results for the Quarter and Six Months ended ... - Jun 30, 2005 Revenue under our contract to co-promote DOVONEX(R) was $5.6 million, a $2.2 million increase over the prior year quarter. Gross Profit on Product Net Sales ... prnewswire.com |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
